BioVie (NASDAQ:BIVI – Get Free Report) and Traws Pharma (NASDAQ:TRAW – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
4.6% of BioVie shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 0.9% of BioVie shares are owned by insiders. Comparatively, 14.0% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for BioVie and Traws Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioVie | 1 | 0 | 0 | 0 | 1.00 |
| Traws Pharma | 1 | 1 | 1 | 1 | 2.50 |
Profitability
This table compares BioVie and Traws Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioVie | N/A | -101.15% | -90.18% |
| Traws Pharma | N/A | -913.18% | -133.88% |
Risk and Volatility
BioVie has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
Valuation and Earnings
This table compares BioVie and Traws Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioVie | N/A | N/A | -$17.54 million | ($2.45) | -0.60 |
| Traws Pharma | $2.79 million | 5.43 | $9.17 million | ($1.69) | -0.88 |
Traws Pharma has higher revenue and earnings than BioVie. Traws Pharma is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.
Summary
Traws Pharma beats BioVie on 10 of the 13 factors compared between the two stocks.
About BioVie
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
About Traws Pharma
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
